{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:09:52Z","timestamp":1772780992529,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ygyno.2010.02.007","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T05:35:20Z","timestamp":1268631320000},"page":"373-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Treatment options for advanced endometrial carcinoma"],"prefix":"10.1016","volume":"117","author":[{"given":"Don S.","family":"Dizon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.02.007_bib1","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.02.007_bib2","series-title":"Global cancer facts & figures\u00a02007","author":"Garcia","year":"2007"},{"key":"10.1016\/j.ygyno.2010.02.007_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/AOG.0b013e318162f690","article-title":"Endometrial cancer","volume":"111","author":"Sorosky","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.02.007_bib5","series-title":"Cancer facts & figures\u00a02008","year":"2008"},{"key":"10.1016\/j.ygyno.2010.02.007_bib6","unstructured":"National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Uterine neoplasms. V.2.2009. Available at www.nccn.org (accessed June 26, 2009)."},{"key":"10.1016\/j.ygyno.2010.02.007_bib7","series-title":"Abeloff's Clinical Oncology","article-title":"Cancer of the endometrium","author":"Park","year":"2008"},{"key":"10.1016\/j.ygyno.2010.02.007_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/00016340802160079","article-title":"Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review","volume":"87","author":"Tinelli","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ygyno.2010.02.007_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#","article-title":"Extracolonic cancer in hereditary nonpolyposis colorectal cancer","volume":"71","author":"Watson","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10689-005-1838-3","article-title":"Gynecologic cancers in Lynch syndrome\/HNPCC","volume":"4","author":"Lu","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1028-4559(08)60102-3","article-title":"Molecular carcinogenesis of endometrial cancer","volume":"46","author":"Liu","year":"2007","journal-title":"Taiwanese J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ygyno.2010.02.007_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ygyno.2010.02.007_bib15","unstructured":"AJCC Cancer Staging Manual 2010, 7th Edition. S Edge, DR Byrd, CC Compton, AG Fritz, FL Greene, A Trotti (Eds). Springer."},{"key":"10.1016\/j.ygyno.2010.02.007_bib16","first-page":"413","article-title":"ACOG practice bulletin, clinical management guidelines for obstetrician\u2013gynecologists, number 65, August 2005: management of endometrial cancer","volume":"106","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2008.01.023","article-title":"Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging","volume":"109","author":"Mariani","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Benedetti Panici","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.02.007_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Kitchener","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.02.007_bib20","first-page":"419","article-title":"Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients","volume":"56","author":"Aalders","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib21","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","article-title":"Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial","volume":"22","author":"Creutzberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jama.295.4.389","article-title":"Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma","volume":"295","author":"Lee","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2010.02.007_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/IGC.0b013e3181a7f71e","article-title":"Management of recurrent endometrioid carcinoma: an overview","volume":"19","author":"van Wijk","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib25","first-page":"650","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers\u2014a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without cisplatin: a Gynecologic Oncology Group study","volume":"112","author":"Homesley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib29","unstructured":"NCT00063999 study synopsis. Randomized phase III trial of doxorubicin\/cisplatin\/paclitaxel and G-CSF versus carboplatin\/paclitaxel in patients with stage III and IV or recurrent endometrial cancer. Available at http:\/\/clinicaltrials.gov (accessed June 5, 2009)."},{"key":"10.1016\/j.ygyno.2010.02.007_bib30","unstructured":"NCT00807768 study synopsis. Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. Updated August 14, 2009. Available at http:\/\/clinicaltrials.gov (accessed August 20, 2009)."},{"key":"10.1016\/j.ygyno.2010.02.007_bib31","unstructured":"NCT00942357 study synopsis. Carboplatin and paclitaxel with or without cisplatin and radiation therapy in treating patients with stage III or stage IVa endometrial cancer. Updated August 14, 2009. Available at http:\/\/clinicaltrials.gov (accessed August 20, 2009)."},{"key":"10.1016\/j.ygyno.2010.02.007_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/annonc\/mdh316","article-title":"Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"15","author":"Fleming","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib33","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0272","article-title":"A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium","volume":"63","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"87","author":"Miller","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib36","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2006.03.043","article-title":"Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"103","author":"Fracasso","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","article-title":"Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group","volume":"111","author":"Garcia","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib40","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 5","key":"10.1016\/j.ygyno.2010.02.007_bib42","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/annonc\/mdm172","article-title":"Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents","volume":"18","author":"Fojo","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib43","first-page":"1981","article-title":"Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry","volume":"2","author":"Kuo","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib44","first-page":"1377","article-title":"Advances in the molecular genetics of endometrial cancer","volume":"6","author":"Esteller","year":"1999","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2010.02.007_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/ijgc-00009577-200601000-00063","article-title":"Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma","volume":"16","author":"Arai","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1677\/ERC-08-0266","article-title":"Resistance to chemotherapy and hormone therapy in endometrial cancer","volume":"16","author":"Chaudhry","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/138920208784533665","article-title":"The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer","volume":"9","author":"Schettino","year":"2008","journal-title":"Curr Genomics"},{"key":"10.1016\/j.ygyno.2010.02.007_bib48","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib49","first-page":"5299","article-title":"Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer","volume":"9","author":"Reed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ygyno.2006.05.020","article-title":"Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association","volume":"103","author":"Weiss","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is class III \u03b2-tubulin a predictive factor in patients receiving tubulin-binding agents","volume":"9","author":"Seve","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib52","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1111\/j.1742-4658.2006.05340.x","article-title":"The \u03b2I\/\u03b2III-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies","volume":"273","author":"Magnani","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.ygyno.2010.02.007_bib53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/088307380301801205","article-title":"Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology","volume":"18","author":"Katsetos","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib54","doi-asserted-by":"crossref","first-page":"12902","DOI":"10.1074\/jbc.M414477200","article-title":"BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability","volume":"280","author":"Kamath","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2010.02.007_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1535-7163.MCT-08-0986","article-title":"Ixabepilone: targeting \u03b2III-tubulin expression in taxane-resistant malignancies","volume":"8","author":"Dumontet","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2010.02.007_bib56","first-page":"207","article-title":"Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin","volume":"27","author":"Umezu","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7164\/antibiotics.49.560","article-title":"Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties","volume":"49","author":"Gerth","year":"1996","journal-title":"J Antibiot"},{"key":"10.1016\/j.ygyno.2010.02.007_bib58","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-008-0727-5","article-title":"Preclinical efficacy spectrum and pharmacokinetics of ixabepilone","volume":"63","author":"Lee","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib60","unstructured":"IXEMPRA\u00ae (ixabepilone) package insert. Bristol-Myers Squibb Company. Princeton, NJ: Bristol-Myers Squibb Company; 2009."},{"key":"10.1016\/j.ygyno.2010.02.007_bib61","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib62","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib63","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roch\u00e9","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib64","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1200\/JCO.2005.02.4448","article-title":"Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-na\u00efve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1200\/JCO.2005.09.042","article-title":"Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer","volume":"23","author":"Galsky","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib66","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.02.007_bib67","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2006.09.7097","article-title":"Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy","volume":"25","author":"Vansteenkiste","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdm591","volume":"19","author":"Burtness","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib69","unstructured":"NCT00883116 study synopsis. A phase III, open-label, randomized, 2 arm study of ixabepilone administered every 21 days versus paclitaxel or doxorubicin administered every 21 days in women with advanced endometrial cancer who have previously been treated with chemotherapy. Updated June 17, 2009. Available at http:\/\/clinicaltrials.gov (accessed June 30, 2009)."},{"key":"10.1016\/j.ygyno.2010.02.007_bib70","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/CCO.0b013e32830b0deb","article-title":"Molecule-targeted agents in endometrial cancer","volume":"20","author":"Delmonte","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib71","doi-asserted-by":"crossref","first-page":"296 s","DOI":"10.1200\/jco.2008.26.15_suppl.5516","article-title":"A phase II study of temsirolimus (CCI-779) in patients with metastatic and\/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib72","doi-asserted-by":"crossref","first-page":"278 s","DOI":"10.1200\/jco.2007.25.18_suppl.5516","article-title":"A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer","volume":"25","author":"Colombo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib73","doi-asserted-by":"crossref","first-page":"293 s","DOI":"10.1200\/jco.2008.26.15_suppl.5502","article-title":"A phase II study of oral mammalian target of rapamycin mTOR inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)","volume":"26","author":"Slomovitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib74","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2007.15.8808","article-title":"Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e16542","article-title":"Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"27","author":"Leslie","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib76","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1158\/1078-0432.CCR-07-1017","article-title":"Clinical and biological significance of vascular endothelial growth factor in endometrial cancer","volume":"13","author":"Kamat","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib77","first-page":"3525","article-title":"Bevacizumab therapy in patients with recurrent uterine neoplasms","volume":"27","author":"Wright","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib78","doi-asserted-by":"crossref","first-page":"284 s","DOI":"10.1200\/jco.2009.27.15_suppl.5531","article-title":"A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study","volume":"27","author":"Aghajanian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib79","doi-asserted-by":"crossref","first-page":"295 s","DOI":"10.1200\/jco.2009.27.15_suppl.5576","article-title":"A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH phase II consortium","volume":"27","author":"Welch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib80","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.1158\/1078-0432.CCR-08-0025","article-title":"Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.02.007_bib81","doi-asserted-by":"crossref","first-page":"47 s","DOI":"10.1200\/jco.2009.27.15_suppl.1029","article-title":"Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa\/bev) versus paclitaxel plus bev (pac\/bev) as first-line therapy for metastatic breast cancer (MBC)","volume":"27","author":"Rugo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.02.007_bib82","unstructured":"NCT00977574 study synopsis. Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in treating patients with Stage III, Stage IV, or recurrent endometrial cancer. Updated February 1, 2010. Available at http:\/\/clinicaltrials.gov (accessed February 2, 2010)."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:24:23Z","timestamp":1758770663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0090825810001356"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.02.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment options for advanced endometrial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}